Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
crisaborole · 1 trial · 1 indication
TSS assesses severity of stasis dermatitis lesions. There were following 4 clinical signs of all treatable stasis dermatitis lesions: erythema, papulation/elevation, superficial erosion/denudation, and scaling. Each of 4 signs were rated on a scale of 0 to 3 (0= none, 1= mild, 2= moderate, 3= severe). TSS = sum of scores from all clinical signs; ranging from 0 (none) to 12 (most severe), where higher score indicated greater severity. The assessment was completed in person by the home visit practitioner.
| Arm | Type | Description |
|---|---|---|
| crisaborole ointment | EXPERIMENTAL | crisaborole ointment |
| vehicle ointment | SHAM_COMPARATOR | vehicle ointment |
| Name | Type | Description |
|---|---|---|
| crisaborole ointment | DRUG | crisaborole ointment |
| vehicle ointment | OTHER | vehicle ointment |
Inclusion Criteria: * Participants who are ≥45 years of age and in generally stable health * Participants who are in generally stable health and have a known diagnosis of Stasis Dermatitis or newly diagnosed Stasis Dermatitis * Participants whose mental and physical status allows them to be able to...
Crisaborole 2% is an investigational small molecule being developed for dermatological conditions, including atopic dermatitis, stasis dermatitis, and healthy skin studies. It is a topical ointment studied for treating mild-to-moderate atopic dermatitis in pediatric and adult patients, with clinical trials conducted across multiple countries.
Crisaborole 2% is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and efficacy of this topical ointment for dermatological indications.
Crisaborole 2% is in Phase 3 clinical development, based on completed Phase 3 trials. It remains investigational and is not yet approved by regulatory authorities. The development program includes multiple completed trials, with the most advanced being Phase 3 studies in atopic dermatitis.
Crisaborole 2% has been studied in several completed clinical trials, including NCT03233529, a Phase 2 skin biomarker biopsy study in atopic dermatitis; NCT03954158, a Phase 2 study in Japanese participants; NCT04040192, a Phase 3 long-term maintenance study; and NCT04360187, a Phase 3 study in Chinese and Japanese subjects.
Crisaborole 2% is the drug name used in clinical trials, and no alternative names have been reported. It is consistently referred to as crisaborole ointment 2% across the studies, with no other brand or generic names mentioned in the available data.